The Hybrid Delusion: RLT, ADC & CDMO Reality
Investors are funding hybrid facilities on the assumption that ADC and radioligand production are operationally similar. This briefing tests that assumption against building physics, air handling, waste regulation and the specialist labour market. In each area the two modalities pull in opposite directions, and the briefing sets out what that does to retrofit economics.
What this report answers
- Can an existing high-potency ADC suite realistically be retrofitted for radioligand production?
- What does a production-scale hot cell do to the structural design of a pharmaceutical building?
- Why is a standard cleanroom exhaust system unusable for alpha-emitter work?
- How scarce is the leadership profile that can run aseptic and nuclear operations at the same time?
- What happens to a hybrid facility's waste when chemical and radiological rules both apply to it?
- What should an investor ask before backing a site marketed as radio-conjugate capable?
18x
the margin by which the briefing calculates a production-scale hot cell exceeds the localised floor loading a standard pharmaceutical cleanroom is designed to carry.
50:1
ProGen Search's estimate of the ratio of qualified candidates for a standard biologics manufacturing role against a specialised radioligand manufacturing role.
What the analysis establishes
Where the building shell decides the answer
The briefing separates containment from shielding and shows why that distinction is structural rather than procedural. It works through the load a production-scale hot cell places on a floor, sets that against how standard pharmaceutical cleanrooms are specified, and details the demolition, foundation and vibration work a retrofit would require - including what changes above ground level in a multi-storey campus.
The atmospheric conflict inside a shared facility
Sterile manufacturing and radiation safety impose opposing pressure regimes, and the briefing sets out how a facility has to nest one inside the other. It then addresses the hazard class that changes everything for alpha emitters, why the filtration an ADC plant depends on does not address it, and what exhaust infrastructure that absence forces you to build.
The capital arithmetic of retrofit against greenfield
The retrofit case rests on the value of an existing shell. The briefing itemises the interventions a conversion actually requires - structural, mechanical and operational - and explains how each one erodes that value, including the cost of paralysing a validated suite next door. It sets out how the comparison against a purpose-built build should be modelled.
The competency profile that governs whether a site can run
The briefing defines the combined skill set a radio-conjugate site leader has to hold, three disciplines with almost no historical overlap and conflicting instincts under pressure. It covers the federal designation without which a facility cannot legally operate, the lead time attached to it, and the pipeline producing those people.
The waste pathway that closes behind you
Radioligand production creates material governed by two federal frameworks that were never designed to intersect. The briefing explains how that entanglement removes the disposal route ADC operations rely on, what the industry pivot to alpha emitters does to commercial acceptance criteria, and the storage duration and vault loading that the remaining option imposes on a site.
The verdict and the diligence questions behind it
The closing section contrasts the integrated all-in-one strategies of the large contract manufacturers with the purpose-built pure-play model, naming operators on both sides. It ends with five forensic questions for operational vetting, each paired with the red flag in the answer, written to be used directly in a 90-day diligence process.
How it was built
A forensic whitepaper rather than a market survey. It reasons from first principles in each domain - shielding physics and structural loading, HVAC and radiological containment, the US waste frameworks, and NRC licensing requirements - and tests the hybrid facility thesis against each in turn. The talent scarcity ratio and the wage premium range are ProGen Search's own market intelligence and are labelled as such. Positions are stated as of November 2025.
Written for investors and diligence teams underwriting radiopharma and ADC manufacturing assets, CDMO boards weighing an all-in-one strategy, and operators planning radioligand capacity.
Contents
- The Convergence Narrative and the Operational Reality Gap
- Part 1: The Physics of Failure
- The Structural Fracture Point: Mass, Density and Floor Loading
- Atmospheric Conflict: The HVAC Wicked Triangle
- The Capital Expenditure Illusion: Retrofit Against Greenfield
- Part 2: The Human Capital and Safety Crisis
- The Trifecta Talent Gap: Anatomy of the Impossible Hire
- The Regulatory Barrier: The Authorized User Bottleneck
- The Mercenary Market and the Human Capital Density Metric
- Part 3: The Strategic Verdict
- The Waste Kill Switch: The Mixed Waste Paradox
- Specialisation Against the High-Risk Hybrid
- The Investor Diligence Playbook: 90-Day Action Plan
Companies, regulators and certifying bodies referenced
AstraZeneca, BMS, Catalent, Curium Pharma, Eli Lilly, Fusion Pharmaceuticals, GE HealthCare, Mariana Oncology, NorthStar Medical Radioisotopes, Novartis, Novo, Nucleus RadioPharma, POINT Biopharma, RayzeBio, Samsung Biologics, WuXi XDC, FDA, EPA, Nuclear Regulatory Commission, American Board of Radiology, American Board of Nuclear Medicine
The full 14-page briefing is free. Tell us where to send it and it downloads immediately.
The State of Radiopharmaceuticals 2026
This briefing covers one question inside the sector. The flagship report covers the sector itself: isotope supply, clinical infrastructure, reimbursement and the operators positioned to hold capacity.
See the full report →